COMPASS Selected for Addition to NASDAQ Biotechnology Index

COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).  For this year’s annual reconstitution, 120 securities will be added to the Index and 16 will be removed.

The NBI is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Exchange traded funds (ETFs) that track the NBI include the ProShares Ultra NASDAQ Biotechnology ETF (BIB), ProShares UltraShort NASDAQ Biotechnology ETF (BIS), Invesco NASDAQ Biotech UCITS ETF (SBIO), and iShares Nasdaq Biotechnology Index Fund (IBB), and others.

We are proud announce our addition to the esteemed Nasdaq Biotechnology Index. Our inclusion in this index enables us to reach new audiences as we continue to execute on our clinical development of our investigational COMP360 psilocybin therapy in hopes of addressing the most challenging issues in mental healthcare.

George Goldsmith, CEO and Founder of Compass Pathways

For more information about the NASDAQ Biotechnology Index visit Overview for NBI (nasdaqomx.com).

To view the original press release in its entirety click here

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More